High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network...

Area of Science:

• Neurology
• Pharmacology
• Nutritional Science

Background:

• Migraine is a prevalent neurological disorder affecting millions globally.
• Current prophylactic treatments for migraine have suboptimal efficacy and safety profiles.
• Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) show promise for migraine prevention.

Purpose of the Study:

• To compare the efficacy and acceptability of various dosages of EPA/DHA with other migraine prophylactic medications.
• To evaluate EPA/DHA as a potential first-choice treatment for migraine prophylaxis.

Main Methods:

• A network meta-analysis (NMA) of randomized controlled trials (RCTs) was conducted.
• Included 40 RCTs with 6616 participants diagnosed with episodic or chronic migraine.
• Primary outcomes were changes in migraine frequency and acceptability; secondary outcomes included response rates and adverse events.

Main Results:

• High-dose EPA/DHA supplementation resulted in the greatest reduction in migraine frequency (SMD: -1.36) and severity (SMD: -2.23) compared to placebo.
• EPA/DHA supplementation also demonstrated the most favorable acceptability rates among all treatments studied.
• These findings indicate superior efficacy and tolerability for high-dose EPA/DHA.

Conclusions:

• High-dose EPA/DHA supplementation is a highly effective and acceptable treatment for migraine prophylaxis.
• This omega-3 intervention can be considered a first-choice option for migraine prevention.
• The study provides compelling evidence supporting EPA/DHA for managing migraine.